Viromed Medical AG, DE000A3MQR65

Viromed Medical AG / DE000A3MQR65

03.12.2024 - 15:00:16

Viromed Medical AG is expanding its Management Board – Christian Strauch has been appointed as a new member of the Management Board

Viromed Medical AG / Key word(s): Personnel


03.12.2024 / 15:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Pinneberg, 3 December 2024 – The Supervisory Board of Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”) has appointed Mr. Christian Strauch as a new member of the company's Management Board with effect from 1 January 2025. The previous sole member of the Management Board, Uwe Perbandt, has been appointed Chairman of the Management Board. "Viromed Medical AG is facing major challenges in the further research, application and global marketing of cold plasma technology. In order to meet these challenges efficiently and successfully, we need to spread the workload across a larger team. In Christian Strauch, we have found an outstanding and internationally experienced expert who, with his extensive know-how, can make a significant contribution to the success of the company," explained Dr. Jan Delphendahl, Chairman of the Supervisory Board of Viromed Medical AG. Christian Strauch has a degree in business administration ("Diplom-Kaufmann") and has many years of experience and a proven track record in building and expanding companies within the healthcare sector. He also has an international network of contacts with decision-makers in the development, manufacturing and distribution of healthcare products. His professional career includes, among other things, more than ten years as a member of the management board of the mail-order pharmacy apo-rot, where he ultimately held the position of managing director. He was also the founder of Linsentaxi GmbH and Pauls Praxis GmbH, as well as the founder and managing partner of pharmedix GmbH. Most recently, he was managing partner of Vameda GmbH, a holding company for corporate investments in the healthcare sector. Uwe Perbandt, former sole member of the Management Board of Viromed Medical AG, added: "I am very much looking forward to working with Christian Strauch in the future. With his experience and contacts, he will actively support and assist me in the next steps of Viromed's growth. This will enable me to focus more on my core competencies and together we can lead the company to success." About Viromed Medical AG: Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region. Viromed Medical AG is pursuing the goal of further advancing the use of CAP in medicine in the coming years and realizing the corresponding growth potential.   Contact Viromed Medical AG Uwe Perbandt
CEO
Flensburger Straße 18
25421 Pinneberg
E-Mail: kontakt@viromed-medical.de
www.viromed-medical-ag.de  


03.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English
Company: Viromed Medical AG
Flensburger Straße 18
25421 Pinneberg
Germany
Phone: +49 4101 809960
E-mail: kontakt@viromed-medical.de
Internet: https://www.viromed-medical-ag.de/
ISIN: DE000A3MQR65
WKN: A3MQR6
Listed: Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt (Basic Board), Hamburg
EQS News ID: 2043367

 
End of News EQS News Service

2043367  03.12.2024 CET/CEST fncls.ssp?fn=show_t_gif&application_id=2043367&application_name=news&site_id=trading_house_net~~~7efceac5-959a-43d6-afef-21ad42b6a5d4
@ dgap.de

Weitere Meldungen

EQS-News: Viromed Medical AG: Kooperation zwischen relyon plasma GmbH und Viromed Medical GmbH (deutsch) Viromed Medical AG: Kooperation zwischen relyon plasma GmbH und Viromed Medical GmbH EQS-News: Viromed Medical AG / Schlagwort(e): Kooperation Viromed Medical AG: Kooperation zwischen relyon plasma GmbH und Viromed Medical GmbH 05.12.2024 / 12:10 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. (Boerse, 05.12.2024 - 12:10) weiterlesen...

EQS-News: Viromed Medical AG erweitert Vorstand - Christian Strauch als neues Vorstandsmitglied berufen (deutsch) Viromed Medical AG erweitert Vorstand - Christian Strauch als neues Vorstandsmitglied berufen EQS-News: Viromed Medical AG / Schlagwort(e): Personalie Viromed Medical AG erweitert Vorstand - Christian Strauch als neues Vorstandsmitglied berufen 03.12.2024 / 15:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. (Boerse, 03.12.2024 - 15:00) weiterlesen...

EQS-Adhoc: Viromed Medical AG plant Erwerb sämtlicher Anteile an der pharmedix GmbH durch Kapitalerhöhung gegen Sacheinlage unter Ausschluss des Bezugsrechts (deutsch) Viromed Medical AG plant Erwerb sämtlicher Anteile an der pharmedix GmbH durch Kapitalerhöhung gegen Sacheinlage unter Ausschluss des Bezugsrechts EQS-Ad-hoc: Viromed Medical AG / Schlagwort(e): Fusionen & Übernahmen Viromed Medical AG plant Erwerb sämtlicher Anteile an der pharmedix GmbH durch Kapitalerhöhung gegen Sacheinlage unter Ausschluss des Bezugsrechts 03.12.2024 / 13:53 CET/CEST Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. (Boerse, 03.12.2024 - 13:53) weiterlesen...

EQS-Adhoc: Viromed Medical AG wird ActivCell Group AG nicht erwerben und fokussiert stattdessen andere strategische Option mit größerem Mehrwert (deutsch) Viromed Medical AG wird ActivCell Group AG nicht erwerben und fokussiert stattdessen andere strategische Option mit größerem Mehrwert EQS-Ad-hoc: Viromed Medical AG / Schlagwort(e): Fusionen & Übernahmen Viromed Medical AG wird ActivCell Group AG nicht erwerben und fokussiert stattdessen andere strategische Option mit größerem Mehrwert 29.11.2024 / 15:06 CET/CEST Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. (Boerse, 29.11.2024 - 15:06) weiterlesen...